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Abstract
Purpose There are controversial debates if patients with Hürthle cell carcinoma, also known as oxyphilic or oncocytic cell
follicular thyroid carcinoma, have a poorer outcome. In this study, we systematically evaluated the clinical outcome in a large
patient cohort following thyroidectomy and initial I-131 radioactive iodine therapy (RIT).
Methods We retrospectively evaluated a total of 378 patients with diagnosed oncocytic follicular Hürthle cell carcinoma (OFTC)
(N = 126) or with classical follicular thyroid carcinoma (FTC) (N = 252). Patients received thyroidectomy and complementary I-
131 RIT. Clinical data regarding basic demographic characteristics, tumor grade, persistent disease and recurrence during follow-
up, and disease-free, disease-specific, and overall survival were collected during follow-up of 6.9 years (interquartile range 3.7;
11.7 years). Univariate and multivariate analyses were used to identify factors associated with disease-related and overall
survival.
Results Before and after matching for risk factors, recurrence was significantly more frequently diagnosed in OFTC patients
during follow-up (17% vs. 8%; p value 0.037). Likewise, OFTC patients presented with a reduced mean disease-free survival of
17.9 years (95%CI 16.0–19.8) vs. 20.1 years (95%CI 19.0–21.1) in FTC patients (p value 0.027). Multivariate analysis revealed
OFTC (HR 0.502; 95%CI 0.309–0.816) as the only independent prognostic factor for disease-free survival. Distant metastases of
OFTC patients were significantly less iodine-avid (p value 0.014). Mean disease-specific and overall survival did not differ
significantly (p value 0.671 and 0.687) during follow-up of median 6.9 years (3.7; 11.7 years).
Conclusions Our study suggests that recurrence is more often seen in OFTC patients. OFTC patients have a poorer prognosis for
disease-free survival. Thus, OFTC and FTC behave differently and should be categorized separately. However, patients suffering
from OFTC present with the same overall and disease-specific survival at the end of follow-up indifferent to FTC patients after
initial RIT.
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Background
The incidence of thyroid cancer has increased globally [1].
Follicular thyroid carcinoma (FTC) is the second most com-
mon epithelial-derived thyroid cancer histotype after papillary
carcinoma (PTC) [1, 2]. The incidence of FTC varies in dif-
ferent regions worldwide most likely depending on the iodine
supply [3, 4]. Hürthle cell carcinoma (OFTC), also known as
oxyphilic or oncocytic cell follicular thyroid carcinoma, rep-
resents about 3–5% of thyroid carcinomas [5–8].
Traditionally, OFTC has been considered as a variant of fol-
licular thyroid cancer [9]. However, the latest thyroid tumor
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classification of the World Health Organization (WHO) of
2017 considered OFTC as an independent type of thyroid
carcinoma and no longer as a subtype of FTC based on dif-
ferences in clinicopathologic features and molecular alter-
ations [8, 10]. Until now, there are controversial debates on
almost all aspects of the disease including diagnosis, staging,
treatment, and prognosis [11]. Some authors have reported a
significantly more aggressive clinical course and a worse
prognosis of both follicular and also papillary OFTC as com-
pared with their non-oncocytic variants [7, 12–14]. In this
context, it has been reported that only a minority of patients
with distant metastasis showed positive I-131 radioactive io-
dine (RAI) uptake of these metastasis which contributes to a
worse prognosis [15]. However, Jillaed et al. have demonstrat-
ed the association of improved survival in OFTC patients who
were treated with radioiodine therapy (RIT) [16]. Recently,
three studies have shown a similar prognosis of FTC and
OFTC patients, especially if influencing risk factors are
matched [11, 17, 18]. In most of the previously published
studies, patients with different standard care procedures were
included. In our department, all patients with OFTC and FTC
have been treated with thyroidectomy followed by initial RIT
on the basis of the same standard at that time of inclusion. Our
goal was to determine patient characteristics and clinical long-
term outcome in terms of disease-free, overall, and disease-
specific survival, recurrence, and persistent disease in patients
with OFTC in comparison with patients with FTC.
Furthermore, we aimed to assess independent prognostic fac-
tors for disease-related and overall mortality.
Methods
Patients
Between 1993 and 2017, 3605 new patients with thyroid car-
cinoma were treated in our department. In this study, only
patients diagnosed with oncocytic variant of follicular carci-
noma (OFTC) and classical FTC with total or near total thy-
roidectomy followed by complementary initial radioiodine
therapy were selected. Oncocytic variant of papillary thyroid
carcinoma was suspended. Patients with a follow-up of less
than 1 year in our center were also excluded. Finally, 378
patients aged over 18 years were enrolled in this study. Of
these, 252 patients (67%) had been diagnosed histologically
with classical FTC and 126 patients (33%) with OFTC. Data
on demographic characteristics, tumor grade, persistent dis-
ease and recurrence during follow-up, and disease-free, dis-
ease-specific, and overall survival were collected. Pathology
reports were reviewed for all patients to confirm the diagnosis
of OFTC and FTC. Histopathology was adjusted to the 8th
edition of the TNM classification of the American Joint
Committee on Cancer (AJCC) in all patients [19, 20].
Treatment and follow-up
All patients were treated with total or near total thyroidecto-
my. Additionally, lymph node dissection was performed in
37% of OFTC patients (N = 47) and in 42% of FTC patients
(N = 106). Afterwards, patients were transferred consecutively
to our clinic where RIT, RAI diagnostic whole-body scan,
follow-up, and other staging examination were performed.
Initial RIT was administered orally either after thyroid hor-
mone withdrawal when TSH level was above 30 μU/ml or
after administration of 0.9 mg recombinant human thyrotropin
alfa (rhTSH; Thyrogen®, Sanofi Genzyme) on two consecu-
tive days with administration of radioiodine 24 h after the
second injection. Between 1993 and November 2013,
3600 MBq I-131 (100 mCi) for patients with pT1/2 pN0 R0
c/pM0, 7400 MBq I-131 (200 mCi) for patients with pT3/4
and/or pN1 and/or R1, and 9200 MBq I-131 (250 mCi) for
patients with known distant metastases (c/pM1) were admin-
istered for initial RIT. After November 2013 until end of study
(2017), administered activity doses were 2000, 3700, 7400,
and 9200 MBq I-131 (54, 100, 200, and 250 mCi) depending
on patient age, TNMR-stage, and risk factors (e.g., Tg out of
proportion, aggressive histology) based on the formerly ATA
guidelines [21–23]. For additional courses of RIT, 7400 MBq
I-131 (200 mCi) was given routinely. However, the final treat-
ment activity could be modified within a certain range by the
treating physician. Eventually, 3700–9200 MBq I-131 (100–
250 mCi) was administered. After RIT, 2% of OFTC patients
(N = 2) and 3% of FTC (N = 7) were treated with external
radiation therapy (ERT) of the neck. During follow-up, serum
TSH levels were maintained at levels < 0.1 μU/ml until 2006
in all patients. Afterwards, in all low-risk patients (T1/2
p/cN0/x cM0) and high-risk patients (pT3, p/cN1, or cM1 or
pR1) presenting no evidence of disease (NED) for more than
5 years, TSH level was maintained at 0.2–0.4 μU/ml (2006–
2009) and at 0.3–0.5 μU/ml (2009–2011) according to our
clinical standard. After 2011, the TSH level was increased to
0.3–1.0 μU/ml in adaption to the ETA and ATA guidelines
[24–26]. In all high-risk patients within the first 5 years and in
all patients with evidence of disease (ED), TSH level was still
maintained at levels < 0.1 μ/ml. In the 1st control during fol-
low-up, a RAI diagnostic whole-body scan was performed in
hypothyroidism or after rhTSH and TSH-stimulated serum
thyroglobulin (Tg) level was measured. Follow-up examina-
tions were usually performed every 3 months in the 1st year,
every 6 months in the 2nd year after treatment, and annually
thereafter. Additional imaging (chest X-ray, computed tomog-
raphy (CT), magnetic resonance imaging, bone scintigraphy,
or positron emission tomography/CT) was performed when
medical physical examination or ultrasound was suspicious
for recurrence or if Tg level was increased. Patients with ED
during follow-up were treated based on a multidisciplinary
tumor board decision including resection of local recurrence;
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resection of cervical lymph nodes; resection of bone metasta-
ses; atypical lung resection; ERT; chemotherapy;
redifferentiation with rosiglitazone or isotretinoin; tyrosine ki-
nase inhibitor (TKI) with lenvatinib, sorafenib, sunitinib, or
pazopanib; and Rhenium-186-HEDP and DOTA-TATE ther-
apies, respectively. Furthermore, 34% of these patients were
treated with a ≥ 1 of these treatment options.
Definition of endpoints
Patient outcomes were compared at four different time points:
1st control after RIT, during follow-up, last visit of follow-up,
and end of study in analogy of a previously published study
[27]: In the 1st control, patients were categorized into two
groups, namely NED and ED. NED was assumed if Tg level
was under the detection limit (1.6 ng/ml 1993–1996; <
1.0 ng/ml 1996–1997, < 0.5 ng/ml after 1998) while Tg re-
covery was in normal range. Additionally, RAI diagnostic
whole-body scan had to be negative and the ultrasound exam-
ination had to show no local recurrence and/or lymphadenop-
athy. During follow-up, the rate of persistent disease and re-
currence were evaluated. Persistent disease was supposed if
stimulated or non-stimulated Tg level remained above the
detection limit and if local recurrence, nodal, and distant me-
tastases were not treated curatively. Recurrence was only eval-
uated in patients with initial M0/Mx status and complete re-
sponse in the first follow-up examination including stimulated
Tg under the detection limit and unsuspicious diagnostic RAI
whole-body scan (N = 242). In these patients, recurrence was
assumed if Tg-level increased above the detection limit or if
tumor lesions were detected during follow-up. Disease-free
survival was defined as the period from the first day of surgery
to the first day of recurrence in M0/Mx patients. Furthermore,
RAI uptake of distant metastases was assessed. Positive up-
take was defined as increased uptake in all metastatic sites.
Vice versa, insufficient uptake was defined as no uptake at all
or only partial uptake of some metastases or initially positive
uptake, but lack of uptake in additional cycles of RIT despite
clinical ED. At the last follow-up visit, the rate of NED and
ED was evaluated again. NED was assumed if Tg was under
the detection rate and cervical sonography, and previous long-
term follow-up of at least 1 year was inconspicuous. The end
of our study included date and cause of death. Overall survival
was defined as the period from surgery to death of any cause.
Disease-specific survival was defined as the period from the
first day of surgery to cancer-specific death. Additionally,
patients were matched to exclude influence on survival in a
subgroup analysis.
Statistical analysis
Analysis was carried out with a statistical package for the
social sciences software package (IBM SPSS, version 25.0,
IBM North America). The quantitative variables were
expressed as median (interquartile range, 25th and 75th per-
centiles), while the categorical ones were presented as num-
bers and percentages. To test normal distribution and compar-
ison of variables between OFTC and FTC patients, the
Kolmogorov-Smirnov test was applied. Comparisons of vari-
ables between patients with OFTC and FTC were performed
using Student’s t test for parametric continuous data, the chi-
quadrat test for ordinal data, Mann-Whitney U test for non-
parametric continuous data, and Fisher exact test for categor-
ical data. Statistical significance was defined as two-tailed p-
values < 0.05. Kaplan-Meier curves were displayed as mean
(95%CI) asmedian survival was not reached. Themultivariate
regression model was applied to analyze prognostic factors
associated with disease-related and overall survival. In the
univariate analysis, gender, age, histology, TNMR stage,
and tumor size have been evaluated based on previously pub-
lished studies [11, 17]. In the multivariate analysis, only pa-
rameters that showed significant influence (p value < 0.05) on
disease-specific or overall survival in the univariate analysis
were included.
Ethics statement
This retrospective study has been conducted in accordance
with the ethical standards, according to the Declaration of
Helsinki, and in accordance with national and international




Patients’ baseline characteristics are presented in Tables 1 and
2. This retrospective study included a total of 378 patients.
Thirty-three percent presented with OFTC (N = 126) and
67% with FTC (N = 252). Of note, at initial diagnosis, FTC
patients presented significantly more often with M1-stage dis-
ease (4% inOFTC patients vs. 16% in FTC patients; p value <
0.001). Most of our patients (64% of OFTC patients and 55%
of FTC patients) were treated with only one cycle of RIT. In
23% of OFTC patients and 21% of FTC patients, two cycles
of RIT were administered. Of note, 20% of our patients (13%
of OFTC patients and 24% of FTC patients) were treated with
≥ 3 cycles of RIT. Only FTC patients were treated with ≥
7 cycles of RIT. Additional treatments are presented in
Table 3. Overall, OFTC patients were followed up for median
7.4 years (3.7; 12.0 years) and FTC patients for 6.6 years (3.7;
11.6 years; p value 0.771).
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Clinical outcome
In the first control after initial RIT, 27% of OFTC patients
(N = 34/126) and 40% of FTC patients (N = 100/252) had still
ED (p value 0.017). Of these, persistent disease was seen in
44% of OFTC patients (N = 15/34) and in 60% of FTC pa-
tients (N = 60/100), however without reaching statistical sig-
nificance (p value 0.115). Apart, recurrence was significantly
more often detected in OFTC patients (N = 16/92, 17%) than
in FTC patients (N = 12/150, 8%; p value 0.037). Recurrence
occurred after 3.2 years (1.4; 7.3 years) in the FTC group and
after 4.2 years (1.6; 4.4 years) in the OFTC group (p value
0.41). Only 19% of recurrent OFTC patients (N = 3/16) and
17% of recurrent FTC patients (N = 2/12) were treated cura-
tively at the end of follow-up (p value 0.887). Mean disease-
free survival was 17.9 years (95% CI 16.0–19.8) in OFTC
Table 2 Patients’ tumor
characteristics and TNM




N = 126 (33%)
FTC
N = 252 (67%)
p value
Tumor size (cm) 3.2 (2.2; 4.5) 3.0 (2.1; 4.5) 3.2 (2.2; 4.4) 0.928
Tumor size ≤ 4 cm 235 (62) 80 (64) 155 (62) 0.922
> 4 cm 92 (24) 30 (24) 62 (25)
Unknown 51 (14) 16 (13) 35 (14)
pT pT1a 11 (3) 2 (2) 9 (4) 0.904
pT1b 61 (16) 23 (18) 38 (15)
pT2 159 (42) 50 (40) 109 (43)
pT3a 79 (21) 28 (22) 51 (20)
pT3b 7 (2) 3 (2) 4 (2)
pT4a 20 (5) 7 (6) 13 (5)
pT4b 5 (1) 1 (< 1) 4 (2)
pTx 36 (10) 12 (9) 24 (10)
pN pN0 136 (36) 42 (33) 94 (37) 0.669
pN1a, pN1b, pN1 17 (5) 5 (4) 12 (5)
pNx 225 (60) 79 (63) 146 (58)
cM cM0, cMx 333 (88) 121 (96) 212 (84) 0.001
pM1/cM1 45 (12) 5 (4) 40 (16)
pR pR0 262 (69) 85 (68) 177 (70) 0.896
pR1 18 (5) 7 (6) 11 (4)
pR2 4 (1) 1 (< 1) 3 (1)
pRx 94 (25) 33 (26) 61 (24)
Quantitative variables were expressed as median (minimum; maximum), while categorical ones were presented as
numbers and percentages
OFTC Hürthle cell carcinoma, FTC follicular thyroid cancer. Significant values (p-value < 0.05) are italicized
Table 1 Patients’ baseline
characteristics for OFTC and FTC Total
N = 378
OFTC
N = 126 (33%)
FTC
N = 252 (67%)
p
value
Age (years) 57.8 (47.0; 68.1) 57.8 (48.8; 67.6) 57.9 (46.5; 68.2) 0.75
Gender (female) 234 (62) 74 (59) 160 (64) 0.432
Time between surgery and RIT
(months)
1.3 (1.1; 1.6) 1.3 (1.0; 1.5) 1.3 (1.2; 1.6) 0.33
Initial RAI dose (MBq) 3720 (3639; 3839) 3740 (3658; 3852) 3701 (3622; 3820) 0.713
> 1 cycle of RIT 159 (42) 46 (37) 113 (45) 0.075
Cumulative RAI dose (MBq) 3853 (3686; 11,585) 3864 (3700; 9978) 3849 (3679; 14,937) 0.967
Follow-up (years) 6.9 (3.7; 11.7) 7.4 (3.7; 12.0) 6.6 (3.7; 11.6) 0.771
Quantitative variables were expressed as median (interquartile range), while categorical ones were presented as
numbers and percentages
OFTC Hürthle cell carcinoma, FTC follicular thyroid cancer, SD standard deviation
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(N = 91, one patient missing) and 20.1 years (95% CI 19.0–
21.1) in FTC patients (N = 150). Five-year, 10-year, and 20-
year disease-free survival were 89%, 77%, and 73% in the
OFTC and 92%, 91%, and 89% in the FTC group (p value
0.027; Fig. 1).
At the end of follow-up, 22% of OFTC patients (N = 28/
126) and 29% of FTC patients (N = 72/252) had ED (p value
0.187). Complete remission (CR), partial remission (PR), sta-
ble disease (SD), and progression (PD) were seen in 78%, 4%,
5%, and 14% in OFTC patients and in 71%, 3%, 4%, and in
21% in FTC patients (p value 0.298).
Furthermore, at the end of our study, 19% of OFTC pa-
tients (N = 24/126) and 17% of FTC patients (N = 42/252) had
died (p value 0.565). Thyroid carcinoma was the cause of
death in 9% of OFTC patients (N = 11/126) and in 10% of
FTC patients (N = 25/252; p value 0.314).
Mean overall survival was 17.5 years (95% CI 15.9–19.2)
in the OFTC group and 17.1 years (95% CI 15.9–18.4) in the
FTC group. Five-year, 10-year, and 20-year overall survival
were 92%, 75%, and 67% in the OFTC group and 91%, 81%,
and 62% in the FTC group, respectively (p value 0.687).
Mean disease-specific survival was 19.9 years (95% CI 8.6–
21.3) in the OFTC group and 18.5 years (95% CI 17.3–19.8)
in the FTC group. Five-year, 10-year, and 20-year disease-
specific survival were 95%, 87%, and 84% in the OFTC group
and 96%, 89%, and 70% in the FTC group, respectively (p
value 0.671; Figs. 2 and 3).
RAI uptake in distant metastases
A total of 2–16 cycles of RIT were performed to treat distant
metastases in 14% of OFTC patients (N = 18) and in 25% of
FTC patients (N = 62). In detail, there are 52 patients with
pulmonary metastases (14 OFTC, 38 FTC), 35 with bone
metastases (6 OFTC, 29 FTC), four with distant mediastinal
and/or hilar metastases (4 FTC), four with liver metastases (1
OFTC, 3 FTC), two with soft tissue metastases (2 FTC), and
one patient with brain metastases (FTC patient). In 17 patients,
distant metastases involved different sites. Of note, in the
OFTC group, only three patients (17%) presented with posi-
tive RAI uptake. On contrast, positive uptake was seen in 32
patients of the FTC group (52%). The difference in RAI up-
take between the OFTC and FTC group was statistically sig-
nificant (p value 0.014).
Risk factors for disease-free, disease-specific, and
overall survival
Tables 4, 5, and 6 reveal the results of regression analysis
made to determine the factors associated with poorer patients’
prognosis for disease-free survival, disease-specific, and over-
all survival for all patients. OFTC is the only risk factor for
disease-free survival in the multivariate analysis. The multi-
variate analysis for overall survival identified advanced age
and T3/4 stages as significant risk factors. The results of mul-
tivariate regression analysis for disease-specific survival re-
vealed that only advanced T3/4 stages were associated with
poorer prognosis.
Matching for patients’ characteristics—subgroup
analysis
Presenting with significant differences in cM1-stage, OFTC
and FTC patients were matched to exclude influence on sur-
vival in a subgroup analysis. Patients were matched by age,
sex, and TNM classification, R-stage, tumor size, and RAI
dose.
There were 310 patients (111 OFTC, 199 FTC) included in
the matched patient group analysis. After matching, 27% of
the OFTC group and 31% of the FTC had evidence of disease
after the 1st RIT (p value 0.517). In patients who presented
with ED in the 1st control, persistent disease was found in
43% of OFTC and in 44% of FTC patients (p value 1.0).
Recurrence during follow-up was detected significantly more
often in OFTC patients than in FTC patients (19% vs. 8%; p
value 0.03). Mean disease-free survival was 17.7 years (95%
CI 15.6–19.7) in the OFTC group (N = 81) and 18.0 years
(95% CI 17.0–18.9) in the FTC group (N = 137). The 5-year,
10-year, and 20-year disease-free survival were 89%, 75%,
and 72% in patients with OFTC and 93%, 91%, and 89% in
patients with FTC, respectively (p value 0.024).








ERT: 6 17 24 1.0
Neck 3 3 6
Brain 1 1 2
Pleura 0 1 1
Bone 2 13 15
Surgical procedures: 10 17 27 0.089
Local recurrence 4 5 9
Cervical lymph nodes 4 5 9
Bone metastasis 2 6 8
Atypical lung resection 3 2 5
Chemotherapy 4 4 8 0.187
Rhenium-186-HEDP 0 1 1 1.0
DOTA-TATE therapy 0 2 2 1.0
Redifferentiation 1 9 10 0.43
TKI 4 7 11 0.452
Thirty-four percent of these patients were treated with ≥ 1 of these treat-
ment options
OFTC Hürthle cell carcinoma, FTC follicular thyroid cancer, ERT exter-
nal radiation therapy, TKI tyrosine kinase inhibitor
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At the last follow-up visit, 23% of the OFTC group and
18% of the FTC had ED (p value 0.373). CR, PR, SD, and PD
were seen in 78%, 5%, 4%, and 14% in OFTC patients and in
82%, 2%, 4%, and 13% in FTC patients (p value 0.412). At
the end of our study, overall mortality rate was 20% of OFTC
and 12% of FTC patients (p value 0.063). Mean overall sur-
vival was 17.3 years (95% CI 15.6–19.1) in the OFTC group
and 17.1 years (95% CI 16.1–18.2) in the FTC group. The 5-
year, 10-year, and 20-year overall survival rate were 92%,
75%, and 66% in patients with OFTC and 94%, 88%, and
71% in patients with FTC respectively (p value 0.075).
Disease-specific mortality rate was 9% in the OFTC and
6% in the FTC group (p value 0.768). Mean disease-specific
survival was 19.8 years (95% CI 18.4–21.3) in the OFTC
group and 18.1 years (95% CI 17.3–19.0) in the FTC group.
The 5-year, 10-year, and 20-year disease-specific survival rate
were 96%, 87%, and 83% in patients with OFTC and 97%,
94%, and 79% in patients with FTC, respectively (p value
0.351).
Discussion
Little is known about the aggressiveness of OFTC in compar-
ison with classical FTC, because OFTC is a relatively rare
disease and less common than other well-differentiated thy-
roid carcinoma. The limited clinical experience and the small
number of available investigational studies make it difficult to
recommend appropriate clinical management and follow-up
strategies. The clinical outcome of OFTC is still discussed
controversially. In fact, four different US studies which
searched for the same outcome and were performed on the
same Surveillance, Epidemiology, and End Results (SEER)
database came to different results [5, 6, 28, 29]. Thus, the
prognosis of OFTC in comparison with classical FTC still
needs to be studied. We aimed to assess the differences in
patients’ characteristics and the clinical outcome in patients
with OFTC compared with patients with FTC. Of note, our
study consists of a large patient cohort following thyroidecto-
my and contemporary initial RIT.
Fig. 1 Disease-free survival in
patients presenting NED in the 1st
control before (a) and after
matching (b). Before and after
matching disease-free survival
was significantly reduced in
OFTC patients in comparison
with FTC patients (before
matching: p value 0.027, after
matching: p value 0.024). OFTC:
follicular Hürthle cell carcinoma;
FTC: classical follicular thyroid
carcinoma
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In our study, OFTC patients presented less often with dis-
tant metastases (4% vs. 16%, p value 0.001). Likewise, in
another study, distant metastasis at presentation was signifi-
cantly less often diagnosed in OFTC patients than in FTC
patients (4% vs. 13%; p value 0.03) [17]. This is in contrast
to a previously published study in which OFTC patients
tended more likely to present with distant metastases (8%
vs. 3%, p value 0.078) [18]. Patients presenting with risk
factors such as advanced tumor stages might have been more
likely transferred to a tertiary care center which has the per-
mission to use higher radiation doses and explaining our rel-
evant number of cM1 patients. However, the relevant and
higher number of FTC patients presenting with cM1 remains
unclear.
We observed that recurrences were more frequently diag-
nosed in OFTC patients than in FTC patients (17% vs. 8%, p
value 0.037), indicating that the oncocytic variant has a more
aggressive course. These findings are in line with a previously
published study including a smaller patient group of 33 OFTC
and 85 FTC patients who were treated by lobectomy, total or
less than the total thyroidectomy followed by RIT in almost
half of the patients [13]. The authors observed that more
OFTC patients developed recurrent disease (24% vs. 8%, p
value 0.05) [13]. In a similar setting, persistence/recurrence
occurred in OFTC patients also more frequently (13% in the
OFTC and 4% in the FTC group, p value 0.011) [18]. In
general, recurrence ranges from 11 to 43% in OFTC patients
[6, 30–32]. Thus, the recurrence rate in OFTC patient is rele-
vant. Furthermore, recurrence was detected almost 1 year ear-
lier in FTC patients than in OFTC patient, although statistical-
ly not significant. It has been described in a previously pub-
lished study that nodules of OFTC were located not in true
lymph nodes but in soft tissues of the neck unassociated with
lymphoid tissue. Furthermore, if lymph node metastases were
present, they were often microscopic (< 5 mm) [33].
Furthermore, the lack of RAI uptake in distant metastases
might have also resulted in a delayed detection of recurrence
in OFTC patients. Thus, diagnosis of these metastases
Fig. 2 Overall survival in OFTC
and FTC patients before (a) and
after matching (b). Overall
survival did not significantly
differ between the two groups
(before matching: p value 0.687,
after matching: p value 0.075).
OFTC: follicular Hürthle cell
carcinoma; FTC: classical
follicular thyroid carcinoma
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Fig. 3 Disease-specific survival
of OFTC and FTC patients before
(a) and after matching (b).
Likewise, no significant
differences could be observed in
disease-specific survival (before
matching: p value 0.671, after
matching: p value 0.351). OFTC:
follicular Hürthle cell carcinoma;
FTC: classical follicular thyroid
carcinoma
Table 4 Risk factors for disease-
free survival Covariate Level Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
Gender Female
Male 1.188 (0.813–1.738) 0.374
Age (years) ≤ 55
> 55
2.4 (1.085–5.31) 0.031 1.605(0.648–3.973) 0.307
Histology FTC
OFTC 0.663 (0.456–0.965) 0.032 0.502 (0.309–0.816) 0.005
T-stage T1/2
T3/4 3.493 (1.505–8.107) 0.004 4.4046 (0.5–32.713) 0.19
N-stage N0/x
N1 6.389 (0.852–47.92) 0.071
R-stage R0/x
R1/2 5.221 (0.672–40.587) 0.114
Tumor size ≤ 4 cm
> 4 cm 3.436 (1.535–7.688) 0.003 0.568 (0.067–4.849) 0.606
OFTC Hürthle cell carcinoma, FTC follicular thyroid cancer, T tumor, N nodus, M metastasis, R resection, HR
hazard ratio, CI confidence interval. Significant values (p-value < 0.05) are italicized
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presents additional challenges [8] which might explain why
recurrence in OFTC patients was detected at a later time point.
In addition, we noticed a poorer disease-free survival in OFTC
patients. In fact, multivariate analysis revealed OFTC as the
only independent prognostic factor for disease-free survival.
All our patients were treated with total or near total thy-
roidectomy followed by initial RIT. In previously published
studies, the percentage of thyroidectomy ranged from 27 to
100% [6, 11, 13, 17, 18, 28, 30–32, 34]. Surgery for thyroid
carcinoma is an important component of a multimodal
Table 5 Risk factors for overall
mortality Covariate Level Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
Gender Female
Male 1.318 (1.032–1.683) 0.027 1.457 (0.956–2.223) 0.08
Age (years) ≤ 55
> 55 8.614 (3.712–19.99) < 0.001 22.608 (2.681–190.657) 0.004
Histology OFTC
FTC 0.95 (0.739–1.221) 0.687 0.724 (0.424–1.236) 0.236
T-stage T1/2
T3/4 5.217 (2.91–9.356) < 0.001 5.024 (1.267–19.924) 0.022
N-stage N0/x
N1 3.057 (1.388–6.731) 0.006 4.621 (0.762–28.028) 0.096
M-stage M0/x
M1 4.529 (2.708–7.575) < 0.001 2.103 (0.798–5.541) 0.133
R-stage R0/x
R1/2 7.463 (3.552–15.68) < 0.001 2.727 (0.949–7.838) 0.062
Tumor size ≤ 4 cm
> 4 cm 2.661 (1.48–4.785) 0.001 0.386 (0.104–1.436) 0.155
OFTC Hürthle cell carcinoma, FTC follicular thyroid cancer, T tumor, N nodus, M metastasis, R resection, HR
hazard ratio, CI confidence interval. Significant values (p-value < 0.05) are italicized
Table 6 Risk factors for disease-
specific mortality Covariate Level Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
Gender Female
Male 1.286 (0.92–1.798) 0.141
Age (years) ≤ 55
> 55 7.106 (2.498–20.211) < 0.001 113,294.32 (0–>1000) 0.926
Histology OFTC
FTC 1.08 (0.757–1.541) 0.671
T-stage T1/2
T3/4 14.92 (5.124–43.441) < 0.001 33.255 (2.857–387100) 0.005
N-stage N0/x
N1 4.286 (1.644–11.174) 0.003 4.546 (0.274–75.38) 0.291
M-stage M0/x
M1 5.835 (2.97–11.462) < 0.001 2.103 (0.798–5.541) 0.231
R-stage R0/x
R1/2 8.88(3.312–23.807) < 0.001 2.077 (0.629–6.866) 0.062
Tumor size ≤ 4 cm
> 4 cm 5.816 (2.46–13.747) < 0.001 0.535 (0.111–2.575) 0.435
OFTC Hürthle cell carcinoma, FTC follicular thyroid cancer, T tumor, N nodus, M metastasis, R resection, HR
hazard ratio, CI confidence interval. Significant values (p-value < 0.05) are italicized
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treatment approach. Former guidelines have suggested total
thyroidectomy as the primary surgical treatment option for
nearly all thyroid carcinoma greater than 1 cm with or without
evidence of loco-regional or distant metastases [35]. The ben-
efit of consecutive RIT in OFTC patients is still not clarified
sufficiently. Certainly, ablative RIT of residual thyroid tissue
can improve early detection of recurrences based on Tg mea-
surement [24]. However, it is claimed that OFTC patients
demonstrate a poorer iodine avidity and are therefore less
responsive to RIT [36]. Indeed, in a previously published
study, most of the knownmetastases did not showRAI uptake
and furthermore not all metastatic sites showed uniform RAI
uptake [15]. In contrast, Besic et al. found radioiodine uptake
in recurrent disease or in distant metastases in 11 of 16 OFTC
patients [37]. Thus, the efficacy of RIT in metastatic OFTC
patients is still controversy. In our study, distant metastases of
OFTC patients were significantly less iodine-avid. Indeed,
only 11% of metastatic OFTC patients have shown RAI up-
take which is in line with a previously published study. In this
study, only 10% of OFTC patients with bone and pulmonary
metastases demonstrated RAI uptake [15]. Nevertheless,
Jillard et al. have shown that survival was significantly im-
proved in OFTC patients (pT1 with N1 or M1, and pT2–4
with any N or M) who received RIT in comparison with
OFTC patients without RIT [16]. Furthermore, it has been
shown in a subgroup analysis that OFTC patients who re-
ceived RIT for adjuvant ablation therapy confer better out-
comes compared either with patients who did not receive
RIT or with patients who received RIT for residual disease
[15]. Thus, in our department, RIT is performed in metastatic
OFTC patients. However, if the use of RIT is limited by miss-
ing RAI uptake, other therapeutic options for these patients
should be discussed in a multidisciplinary tumor board.
Our intention was much more to analyze if OFTC patients
have a poorer outcome than FTC patients due to a more ag-
gressive histology or to different risk factors. Therefore, we
performed a Cox regression analysis to determine risk factors
which were associated with poorer disease-specific and over-
all survival. Independent prognostic factors for disease-
specific survival are described inconsistently. Male gender,
advanced age of patients, advanced TNM (tumor, nodes, me-
tastasis) stages, and residual tumor after thyroidectomy have
been noted to influence outcome negatively [11, 13, 18, 29,
30, 34, 38–40]. In our study, we could also identify these risk
factors in the univariate analysis. Interestingly, tumor size of
> 4 cm was a risk factor for overall and disease-specific sur-
vival in the univariate but not in the multivariate analysis.
Indeed, it is still debatable if tumor size represents a risk factor
at all [30, 32]. In our study, T-stage was the only risk factor
that was identified in the multivariate analysis. Besides tumor
size, gross extrathyroidal extension invading strap muscles or
into major neck structures is part of the definition of T. Indeed,
extrathyroidal extension was identified as a risk factor by
others [15, 34, 38]. Thus, T-stage including gross
extrathyroidal extension may be even more associated with
poorer survival than the tumor size itself. However, the histo-
logical variant (OFTC vs. FTC) was not a risk factor for over-
all and disease-specific survival per se. At the end of our
study, patients suffering from OFTC presented with the same
overall and disease-specific survival at the end of follow-up
indifferent to FTC patients after a follow-up time of almost
7 years.
Limitations
Firstly, the main limitation certainly represents the retrospec-
tive design; also, this study is from a single center.
Histopathological data had to be adjusted to the 8th edition
of UICC in order to compare TNM status. As a consequence,
in some patients, TNM classification could not be adapted.
Furthermore, at the time of inclusion, SPECT or even hybrid
imaging was not available and consequently reliable differen-
tiation between thyroid remnant tissue and radioiodine-avid
lymph node metastases was not possible. Furthermore, at the
time of inclusion, Tg assays were not as sensitive as today
which might have hampered early detection of recurrence.
Furthermore, the treatment regimens varied over time ranging
from a quite aggressive approach up to a more personalized
therapy which takes various risk factors into account.
However, this shift applies to both groups equally. We fo-
cused on the long-term outcome, and therefore, we had to
include these patients. Indeed, we still believe that our results
can be transferred to patients nowadays. Last, the median
follow-up time of almost 7 years might be too short to observe
differences in overall and disease-specific survival. The good
overall prognosis of differentiated FTC and OFTC may re-
quire a large patient cohort and an extreme long-term fol-
low-up to show differences in survival.
Conclusion
Our study suggests that recurrence is more often seen in
OFTC patients. Furthermore, OFTC patients have a poorer
patients’ prognosis for disease-free survival. However,
OFTC patients present with the same overall and disease-
specific survival indifferent to FTC patients after initial RIT.
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